Aller au contenu principal
2026 conference-abstract

Abstract 1126: Pervasive early dissemination in pancreatic cancer uncovered by tissue-paired plasma whole-genomes

0Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : ca, de. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract In pancreatic cancer, 50% of the patients are diagnosed at the metastatic stage due to a lack of symptoms. The overall survival rate dramatically reduces from 44% in early-stage resectable patients to 3% in metastatic cases. However, even in early-stage patients, >75% of them still recur after resection and adjuvant therapies. Therefore, there is an urgent need to develop a sensitive strategy to detect this disease earlier before it spreads. Characterizing circulating tumor DNA (ctDNA) in plasma is an effective approach to detect and monitor cancer. Whole-genome sequencing (WGS) tracks all the tumor mutations simultaneously, and has a higher sensitivity than targeted approaches, especially in samples with extremely low tumor burden. In this study, to investigate the ctDNA dynamics and early dissemination in pancreatic cancer, we established a cohort of 1,013 samples from 277 donors, including plasma WGS at 20-60x, alongside germline DNA WGS, tissue WGS and transcriptomic sequencing. Using a tumor-guided approach, we found that the early-stage resectable cases shed very little ctDNA (<1% tumor fraction, TFx). Plasma TFx levels were elevated at the metastatic stage, but were also dependent on metastatic tissue site, where patients with liver metastases had higher TFx than the ones with only non-hepatic lesions. We further discovered the tumor-intrinsic features that were related to increasing ctDNA shedding, such as whole-genome duplication (WGD), high cell cycle activity and non-glandular morphology, as well as extrinsic features related to reduced shedding, including a reactive microenvironment and B cell immunity. Our analysis on tumor clonal architecture revealed that subclonal mutations were more frequently detected than the clonal ones in plasma samples with low ctDNA levels or from early-stage patients, which strongly suggests that dissemination from early-stage primary tumors mostly derived from subclones. In the longitudinal plasma, we observed that subclones seeded metastasis years before imaging diagnosis. This study with a unique large cohort of paired tumor and plasma sequencing data provided a comprehensive insight on ctDNA dynamics, disease monitoring and early detection in pancreatic cancer. Citation Format: Yuanchang Fang, Michelle Chan-Seng-Yue, Karen Ng, Amy Zhang, Tuan Hoang, Gun Ho Jang, Sabiq Chaudhary, Catia Gaspar, Eugenia Flores-Figueroa, Daniela Bevacqua, Stephanie Ramotar, Ayelet Borgida, Shawn Hutchinson, Anna Dodd, Barbara Grünwald, Julie Wilson, Robert Grant, Erica Tsang, George Zogopoulos, Masoom Haider, Jennifer Knox, Steven Gallinger, Faiyaz Notta. Pervasive early dissemination in pancreatic cancer uncovered by tissue-paired plasma whole-genomes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1126.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Abstract 1126: Pervasive early dissemination in pancreatic cancer uncovered by tissue-paired plasma whole-genomes
Date Crossref
03/04/2026
Éditeur
American Association for Cancer Research (AACR)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • University of Toronto pays non établi dans la notice
    Université ou école supérieure
  • Ontario Institute for Cancer Research pays non établi dans la notice
    Organisme public
  • University Health Network pays non établi dans la notice
    Établissement de santé
  • Essen University Hospital pays non établi dans la notice
    Organisme public
  • McGill University pays non établi dans la notice
    Université ou école supérieure
  • Montreal pays non établi dans la notice
    Institution

University of Toronto, Ontario Institute for Cancer Research et University Health Network, avec 3 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomicsCancer Cells and Metastasis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.